NCT05564286View on ClinicalTrials.gov

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

July 31, 2023

Study Completion Date

August 30, 2023

Conditions
Cervical CancerNasopharyngeal CancerChemotherapy-induced Nausea and VomitingRadiation-Induced Nausea and VomitingAntiemetic
Interventions
DRUG

Fosaprepitant

In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .

DRUG

tropisetron

All patients received tropisetron 5mg on day 1.

DRUG

Dexamethasone

.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.

Trial Locations (1)

515031

Cancer Hospital of Shantou University Medical College, Shantou

All Listed Sponsors
lead

Shantou University Medical College

OTHER